The Cell Index Database, (CELLX) (http://cellx.sourceforge.net) provides a computational framework for integrating expression, copy number variation, mutation, compound activity, and meta data from cancer cells. CELLX provides the computational biologist a quick way to perform routine analyses as well as the means to rapidly integrate data for offline analysis. Data is accessible through a web interface which utilizes R to generate plots and perform clustering, correlations, and statistical tests for associations within and between data types for ~20,000 samples from TCGA, CCLE, Sanger, GSK, GEO, GTEx, and other public sources. We show how CELLX supports precision oncology through indications discovery, biomarker evaluation, and cell line screening analysis.
Introduction
To support precision medicine patient selection strategies, genomics data is used to identify oncogenic drivers or dysregulated pathways in cancer cells susceptible to therapeutic intervention. Notably, efforts by The Cancer Genome Atlas (TCGA, http://cancergenome.nih.gov), the Cancer Cell Line Encyclopedia (CCLE) [1] , and Sanger Wellcome Trust Genomics of Drug Sensitivity in Cancer (GDSC) [2] have generated a plethora of data and datatypes that can be used for generating patient selection hypotheses. However, multiple genomics data types such as expression, copy number variation (CNV), and mutation are large and unwieldy to manage. For the computational biologist, much time and effort can be spent to assemble an up to date table of features which can be computed on because new data are often generated frequently and incrementally. Thus, there is a need for an infrastructure to perform simple, quick, and routine analyses on multi-dimensional genomics data as well as the automated assembly of data tables for offline computation using more sophisticated algorithms. 
Biomarker Frequency Reports
Tables of the frequency of alterations across datasets can help to prioritize indications for therapies with known biomarkers. For instance, the venn report of the frequency of CDK4 biomarker alterations within datasets shows significant frequencies of CDK4 amplification in sarcoma, gliomas, and melanoma TCGA datasets (Table 1) . Cutoffs can be defined by expression level, CNV level, and/or mutation status. The co-occurrence or exclusion of 2-4 biomarkers within the same sample can also be quantified.
Analysis
CELLX can identify genes whose expression correlates with a gene of interest and return a table of significant genes that can be visualized via a heat map with labelled metadata. For example, a search for genes correlated with CDK4 expression in the TCGA sarcoma dataset yields ACVRL1 which is expressed by vascular endothelium and a potential anti-angiogenesis target. (Figure 4a ) Table 1 . Frequency report for CDK4 alterations in TCGA. CDK4_c is the number of samples in which the CNV exceeds the set threshold, in this case ~4 copies. CDK4_m is the number of samples with a CDK4 mutation. The cells_c/_m columns are the number of samples for which CNV or mutation data are available, respectively. Percentages are calculated as altered / total for each individual alteration type.
A scatter plot of CDK4 vs. ACVRL1 shows higher ACVRL1 in Dedifferentiated Liposarcomas (DDPLS) vs. Leiomyosarcomas ( Figure 4b ). This is consistent with a study reporting immature and intermediate blood vessels in sarcomas and quantifying tumor microvessel density that is ~3X higher in DDLPS vs. Leiomyosarcomas. [9] The plot also shows that CDK4 expression is high in DDLPS and often focally amplified which is consistent with the literature. [10] CELLX can also . test for significant gene expression associated with meta data features by performing a t-test of a gene's expression grouped by a sample's meta data. As an example, a search for meta data with significantly different CDK4 expression in the TCGA sarcoma dataset reveals that the histologic diagnosis type has large differences in CDK4 expression levels (lowest p-val = 2.54e -19 ) as calculated by a pairwise t-test between all groups (Figure 4c) . A box plot of the groups from histologic diagnosis shows that the CDK4 values from DDPLS are higher than other sarcomas (Figure 4d ). Additional types of analyses include the identification of differentially expressed genes using t-tests of gene expression between groups defined by a gene's expression, a gene's mutation status, or a meta value label. For example, one could ask what genes are differentially expressed between samples with high CDK4 vs. low CDK4, samples with mutated EGFR vs. wild type EGFR, or samples annotated as male vs. female. Conversely, one can search for mutated genes which differentially express the query gene. e.g. which gene(s) mutations have higher or lower expression of EGFR than wild-type.
Precision Medicine
To support precision medicine, CELLX can be used to generate responder / non-responder hypotheses from cell line screening data. As a retrospective example, one can analyze the cell line sensitivity profile of Palbociclib, a CDK4/6 inhibitor under development for ER+ breast cancer. Published breast cell line IC50 values for Palbociclib [11] show a range of responses. (Figure 5a ) CELLX can associate IC50 values with cell line expression, CNV, and mutation data from data sources such as CCLE. Samples divided into two groups by user defined cutoffs, in this case <1uM for responder cell lines (LOW IC50) and > 1uM for non-responder cell lines (HIGH IC50) can be used to identify genes whose expression is significantly different between responder and non-responder cells by calculating t-tests on the expression of ~20,000 genes and displaying a pvalue ranked table (Figure 5b ). Hierarchical clustering on the top 100 most significant genes, ordering the samples from low to high IC50, and coloring the samples by intrinsic breast subtype as defined by PAM50 [12] shows that luminal B and Her2 subtypes tend to be sensitive to Palbociclib whereas cells of the basal subtype tend to be resistant (Figure 5c ). Luminal A cell line subtypes were not represented in the screening set. Additionally, CELLX can dynamically generate a combination CNV / mutation table for genes which meet user defined amplification / deletion thresholds or have annotated mutations. A ranked table of p-values from Fisher's exact test for all genes with either a CNV or mutation alteration (Table 2) highlights genes potentially associated with compound activity. While individually, the appearance of any one gene is not necessarily significant, together the combined results from the expression, CNV, and mutation associations highlight RB1, CCNE1, and to a lesser extent CDKN2A. Specifically, the expression of RB1 was low in resistant cells whereas CDKN2A and CCNE1 were high in resistant cells. Interestingly, unlike other targeted therapies where the small molecule target is often the biomarker of sensitivity (e.g. EGFR, MET, BRAF) the significant Palbociclib biomarkers represent markers of resistance. RB1 deficiency (CNV deletion, STOP mutations, and low expression) and concomitant high CDKN2A expression [13] are characteristics of the basal or triple negative breast subtype status (Figure 5c ). Thus, if most of the RB1 deficient samples belong to the triple negative subtype, the remaining luminal A/B (ER+/ERBB2+/-) and ERBB2+ segments would be enriched for possible CDK4i responders. In support of this notion, luminal B and Her2 breast subtype cell lines are mostly sensitive to CDK4i (Figure 5c ).
!
CELLX can also confirm if the low RB1 expression found in triple negative breast cell lines also occurs in primary tissues by using the TCGA-BRCA breast invasive carcinoma dataset. CELLX can identify the genes that are most differentially expressed between RB1 high (> 9.5) vs. RB1 low (< 9.5) expressing cells using t-tests. Several of the top 100 ranking genes by p-value are related to cell cycle (RB1, CDKN2A, CCNE1) or DNA replication/repair (RFC2, RFC4, MCM5, MCM7, CDT1, NASP, POLK, POLD1, MUTYH, FANCE). Hierarchical clustering and labeling with the intrinsic subtype via PAM50 [12] shows that similar to cell lines, we find that tumors with low RB1 and high CCNE1/CDKN2A expression are often of the basal subtype ( Figure 6 ). ZR7530_LOW  CAMA1_LOW  MDAMB134VI_LOW  HCC202_LOW  UACC893_LOW  EFM19_LOW  EFM192A_LOW  MDAMB361_LOW  HCC1500_LOW  HCC1419_LOW  MDAMB415_LOW  HCC38_LOW  UACC812_LOW  HCC2218_LOW  ZR751_LOW  MDAMB453_LOW  T47D_LOW  MCF7_LOW  BT20_LOW  BT474_LOW  SKBR3_LOW  KPL1_LOW  HCC1143_LOW  MDAMB231_LOW  HCC1395_LOW  HS578T_LOW  CAL51_LOW  HCC1569_HIGH  HCC70_HIGH  HCC1187_HIGH  HCC1954_HIGH  MDAMB468_HIGH  HCC1806_HIGH  MDAMB436_HIGH  DU4475_HIGH  MDAMB157_HIGH  BT549_HIGH  HCC1937_HIGH   SLC9A2  UHRF1BP1L  FREM2  DEGS2  KIAA1324  ZG16B  TBC1D30  PRRT3  THSD4  LARGE  RB1  DCAF5  PER2  RUNDC1  HERC1  PI3  CDKN2A  CMPK2  CARD6  LYN  IFIT2  IFIT3  B3GNT5  CCDC82  FMNL2  RGS2  HHLA3  NUPL2  OAF  TMEM39B  C19orf66  RNF19B  SPATA24  PLAGL1  KANK4  NRN1  RSAD2  LAMA4  SLC1A3  PTGS2  CCL5  LOC375196  SOX8  CLDN11  PLXNA2  FAM89A  HOXA1  MIR31HG  MAML2  ICAM1  RTP4  CASP1  CARD16  CTSS  BTN3A3  NLRC5  HCP5  TAPSAR1  PLIN2  CEBPD  CCNE1  TTYH3  HLA.F  NCOA7  STX10  CDCA8  TOB1  CENPW  CDC20  CSTB  TMBIM6  CLTC  TFF1  CLDN3  SPDEF  GPR160  CA12  ARL1  GNPNAT1  CSAD  FAM177A1  RGL2  CANT1  GNS  RAB11A  LMCD1  RSAD1  SPATA20  PTPN11  DIP2B  GNPTAB  SLC39A9  SERF2  POC1B  TMTC3  WHAMM  RNF103  SPTLC2  MON2 MDAMB175  ZR7530  CAMA1  MDAMB134VI  HCC202  UACC893  EFM19  SUM190  EFM192A  MDAMB361  HCC1500  HCC1419  MDAMB415  HCC38  MCF10A  UACC812  HCC2218  ZR751  MDAMB453  184A1  T47D  MCF7  BT20  MDAMB435  BT474  SKBR3  KPL1  HCC1143  MDAMB231  HCC1395  SUM225CWN  HS578T  184B5  UACC732  CAL51  HCC1569  COLO824  HCC70  HCC1187  HCC1954  MDAMB468  HCC1806  MDAMB436  DU4475  MDAMB157  BT549  HCC1937 PD0332991 data 
Summary
CELLX is an informatics infrastructure to manage multi-dimensional genomics datasets containing expression, copy number variation, mutation, and compound sensitivity information. A browser based web page enables an accessible way to visualize, analyze, and download the database data in a pre-formatted ! focused on supporting oncology precision medicine through the evaluation of preconceived hypotheses as well as unbiased, data driven hypothesis generation. Though usable by the general user, CELLX is aimed at the computational biologist who desires more control over the data or wants to integrate custom data not available in public databases.
Data Processing
When available, summarized data from the source was used for TCGA, CCLE, and Tumorscape except for CNV calls. If Affymetrix SNP files were available, they were processed relative to the hg18 assembly using the aroma.affymetrix R package according to the methods of H. Bengtsson et al. [14] using the average baseline of 128 female HapMap samples [15] as the reference to maintain consistency and comparability across datasets. Microarray expression data from GEO, Sanger, and CCLE were GC Robust Multiarray Average normalized using R and the gcrma [16] library. Comparable to the TCGA RNA-Seq RSEM pipeline, CCLE RNA-Seq [17] data was processed using RSEM [8] on RefSeq sequences, quartile normalized to 1000, and log2 transformed. The R library genefu [18] predicted PAM50 subtypes and genefilter [19] enabled fast t-tests, F-tests, and correlations. Plots were made using CELLX and edited using Preview and Pages.
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